RSS
 

Posts Tagged ‘lindsay rosenwald’

J&J’s abiraterone acetate increases survival in prostate cancer patients

12 Jan

In October 2010, Johnson & Johnson presented its second stage of Phase III trial analysis at the European Society for Medical Oncology congress. The agent under investigation was a novel and promising drug, abiraterone acetate, which demonstrated positive results in increasing survival in patients with advanced prostate cancer.

The COU-AA-301 randomized, placebo-controlled trial involved 1,195 patients with castrate-resistant prostate cancer (another name for metastatic advanced prostate cancer). The disease progressed after receiving chemotherapy based on Taxotere (docetaxel). One group of 797 men was treated with abiraterone acetate plus low-dose prednisone, and another group of 398 patients was treated with placebo plus prednisone/prednisolone. The abiraterone group demonstrated increased median survival to 14.8 months compared to 10.9 of the placebo group. Although 3.9 months seems not very much, but according to Lindsay Rosenwald and Johann de Bono, only four drugs in the history of prostate cancer had survival benefit; and abiraterone is likely to bring the change to the lives of patients with advanced prostate cancer.

36 percent of patients treated with abiraterone acetate had median survival and 35 percent had fatal outcome risks compared with patients in the placebo group. Furthermore, patients, who received abiraterone had significant improvement in secondary endpoints, including TTPP or time to PSA progression as well as RPFS or radiographic progression-free survival.

In September 2010, when the trial data demonstrated significant survival improvement, the analysts recommended that the patients treated with placebo in the Phase III study should be offered abiraterone acetate. In late 2010, Johnson & Johnson filed marketing applications for the approval of abiraterone acetate. If approved by FDA, the drug will be distributed in the U.S. and Europe by mid-2011; and then will follow in the rest of the world according to local regulations. Lindsay Rosenwald, MD, one of the lead investors in the biotechnology sector, noted that abiraterone acetate could become a very promising candidate that can bring difference to patients with advanced prostate cancer.

 
Comments Off

Posted in Lindsay Biotechnology

 

Achievements Of Dr. Lindsay Rosenwald Serve As A Source Of Inspiration For The Youth

10 Jun

In 1991, Dr. Lindsay Rosenwald has led to the achievements in the field of bio technology and medical research. His company soon emerged as basis for the development of other portfolio companies. There are many achievements made by Rosenwald and his group of companies and they are one of the most trusted and most famous companies in the market.

There are many portfolio companies involved in the drug research. There is a separate company which is intended for the co-ordination and facilitation of drug development and drug research in these companies, which are founded by Dr. Lindsay Rosenwald. It is also involved in the general corporate development of the portfolio companies of the group.  Another group is a multi national company. This health care investment company concentrates on the concepts that produce new drugs and also the companies which try to produce them. The main of this company is to provide support to these sprouting new companies. It is crucial in finding the financial support to the portfolio companies. Bio Capital is a broker dealer company that has a valid registration. It is registered with Financial Industry Regulatory Authority which is usually abbreviated as FINRA. The success of Bio Capital Company can be known by looking at the statistics of the company and the fund raised by the company. Till now, the company has raised a whooping amount of nine hundred and fifty million dollars for the development of portfolio companies. All these companies are initiated by Rosenwald. When coming to the life story of Rosenwald, he has done his schooling in Pennsylvania till the year 1973. Then he wanted to join in finance course at masters’ level. So, he moved to Pennsylvania State University. He has completed his graduation in Beta Sigma Gamma in the year 1977. Then he took up medicine studies at Temple University’s school of medicine. After completing his medicine studies in 1983 he joined his internship in Abington Medical Hospital. At the same time, he has started his own practice.

Lindsay Rosenwald has a passion towards finance field and it has led him to move to Wall Street. There he emerged in to a unique person by taking two professions at the same time. They are medical practitioner and analyst.  It is a unique kind of job where he is the first of his kind. Rosenwald got fame in both the professions and he is considered as legend in associating bio technology and life sciences with financial world. His initiations has now seen in the form of bigger companies which are considered as pioneer in their respective fields.

 
Comments Off

Posted in Lindsay Biotechnology

 

Lindsay Rosenwald Accomplishments

22 May

Immediately after going to Abington High School, Dr. Rosenwald began his health care training at PSU in 1973. He had a fascination with exactly how businesses worked and spent a fair amount of time learning about the financial features of their operation.

In pursuit of his lifelong wish, Lindsay Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before beginning his own private practice. After filling out his internship, he functioned as a medical professional in his private practice for 2.5 years. Though he liked practicing medicine Dr. Rosenwald sensed as if something was absent. He made the decision he needed to combine his 2 interests, business enterprise and medical science, and look for a career that would let him pursue those passions.

Lindsay Rosenwald eventually left his private practice in 1986 to go to Wall Street where he got on a position as a Physician / Analyst, an extremely exclusive placement with just a few people doing it at that time. In spite of the belief that doctors don’t make good investors, Dr Rosenwald excelled at this job. He worked here because he felt it was vital to focus on opportunities in the medicine and health sector. He received superb respect in his brand new position, and although he missed his old private practice, he knew this is where he truly belonged. He also worked for an exclusive investment company, DH Blair Co as the Controlling Director of Finance, but left after a few years to concentrate on a brand new enterprise.

With time, he has widened this company by establishing new companies and gaining control of other biotech firms. The business has financed more than two dozen businesses in the last three years. He is able to make these acquired companies successful because he focuses on both improving the corporate framework of the organization. All of these companies are separate entities, but interact to aid each other. The businesses that Rosenwald handles have licensed or obtained over a hundred experimental stage medicines.

Possibly one of Dr Rosenwald’s greatest accomplishments is that he set the record for the fastest development of a drug. In only thirty months, Arsenic Trioxide was developed and approved by the FDA for treating a deadly type of the leukemia disease. This medicine has been on the market worldwide for more than ten years and it has saved and extended 1000s of lives.

Rosenwald has been revolutionary with the firms he has created. One of his businesses sold to J&J for over One Billion Dollars despite the fact that they only had one medicine with phase 2 data. He is also the cause of bringing a stem cell business, a cancer vaccine organization, and a gene therapy company all to market. As Rosenwald as the leader, his companies have created many of the most valuable and groundbreaking drugs of the 21st century. To add to his achievements he created the first successful medicine to assist those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is he employs PHDs, MDs, MBAs, and other experts to function as his senior level professionals. These people provide plenty of experience in both the medical and business arenas that will help make his businesses more powerful and more diverse. They are driven to create new medicines as fast as possible. A few of these drugs have the potential to alter the way we view medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to medical and science instruction to help create the future of medicine.

Lots of people credit the success of the biotech industry on a whole to Dr. Lindsay Rosenwald. His visionary companies have altered many lives and made Dr. Rosenwald’s personal assets soar to the tune of $600 million.

 
Comments Off

Posted in lindsay rosenwald

 
« Older Entries
Newer Entries »